PEG-Glucocerebrosidase for the Treatment of Gaucher Disease
NCT ID: NCT00001410
Last Updated: 2008-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
1993-10-31
2001-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Type I is the most common form. It is a chronic non-neuronopathic form, meaning the disease does not affect the nervous system. The symptoms of type I can appear at any age.
Type 2 Gaucher disease presents prenatally or in infancy and usually results in death for the patient. Type 2 is an acute neuronopathic form and can affect the brain stem. It is the most severe form of the disease.
Type 3 Gaucher disease is also neuronopathic, however it is subacute in nature. This means the course of the illness lies somewhere between long-term (chronic) and short-term (acute).
Currently there is not a cure for Gaucher disease. Treatment for the disease has traditionally been supportive. In some severely affected patients, bone-marrow transplants have corrected the enzyme deficiency, but it is considered a high-risk procedure and recovery can be very slow. Enzyme replacement therapy is another therapy option and has been approved by the Food and Drug Administration (FDA) for use in type 1 patients.
PEG-glucocerbrosidase is a drug designed to clear out the accumulation of lipid (glucocerebroside) from the blood stream. The drug is actually an enzyme attached to large molecules called polyethylene glycol (PEG). The large molecules of PEG allow the enzyme to remain in the blood stream for long periods of time. By modifying glucocerebrosidase with PEG, it is believed that smaller doses will be required, meaning a reduction in cost for the patient and more convenient administration of the drug. The purpose of this study is to evaluate the effects and safety of enzyme replacement therapy using PEG- glucocerebrosidase for the treatment of Gaucher disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Enzyme Replacement in Gaucher's Disease
NCT00001289
Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells
NCT00001234
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease
NCT00465062
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
NCT00954460
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
NCT00004293
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lysodase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Must have a biochemically confirmed (enzyme) and/or genetically confirmed diagnosis of type 1 or type 3 Gaucher disease.
Clinical or laboratory signs suggesting need for therapy which will include at least 2 of the following: hemoglobin less than 11 gm/dl; platelets less than 90,000/mm(3); hepatomegaly and/or splenomegaly.
Patient/Guardian must provide written informed consent.
No pregnant or breast feeding women.
No women/men of reproductive potential unless they agree to use an effective contraceptive method.
No patients treated with alglucerase or imiglucerase during the 6 months prior to study entry.
No patients with the diagnosis of type 2 Gaucher disease.
No patients who have a life-threatening disease or are gravely ill.
No patients who have rapidly progressing fatal illness or concomitant malignancy.
No patients who have a chronic infectious disease including HIV or hepatitis B.
No patients chronically on other medications which may interfere with the drug's metabolism or activity.
No patients who received blood transfusion within a month prior to study entry.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Mental Health (NIMH)
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Martin BM, Sidransky E, Ginns EI. Gaucher's disease: advances and challenges. Adv Pediatr. 1989;36:277-306. No abstract available.
Martin BM, Tsuji S, LaMarca ME, Maysak K, Eliason W, Ginns EI. Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector. DNA. 1988 Mar;7(2):99-106. doi: 10.1089/dna.1988.7.99.
Rappeport JM, Ginns EI. Bone-marrow transplantation in severe Gaucher's disease. N Engl J Med. 1984 Jul 12;311(2):84-8. doi: 10.1056/NEJM198407123110203.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
94-M-0014
Identifier Type: -
Identifier Source: secondary_id
940014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.